Evidence map›Paper›PMID 30642974›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2019

Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope.

Feng Long, Michael Doyle, Estefania Fernandez, Andrew S Miller, Thomas Klose, Madhumati Sevvana, Aubrey Bryan, Edgar Davidson, Benjamin J Doranz, Richard J Kuhn and 3 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
8.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Cryo-Electron Microscopy-Based Epitope Mapping.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Flavivirus Entry Inhibitors.Advances in experimental medicine and biology · 2022
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Feng LongDepartment of Biological Sciences, Purdue University, West Lafayette, IN 47907.
Michael DoyleDepartment of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN 37232.
Estefania FernandezDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110.
Andrew S MillerDepartment of Biological Sciences, Purdue University, West Lafayette, IN 47907.
Thomas KloseDepartment of Biological Sciences, Purdue University, West Lafayette, IN 47907.ORCID 0000-0002-2150-9792
Madhumati SevvanaDepartment of Biological Sciences, Purdue University, West Lafayette, IN 47907.
Aubrey BryanIntegral Molecular Inc., Philadelphia, PA 19104.
Edgar DavidsonIntegral Molecular Inc., Philadelphia, PA 19104.
Benjamin J DoranzIntegral Molecular Inc., Philadelphia, PA 19104.
Richard J KuhnDepartment of Biological Sciences, Purdue University, West Lafayette, IN 47907.ORCID 0000-0003-4148-1026
Michael S DiamondDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110.
James E CroweDepartment of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN 37232.ORCID 0000-0002-0049-1079
Michael G RossmannDepartment of Biological Sciences, Purdue University, West Lafayette, IN 47907; mr@purdue.edu.
Purdue University West Lafayette · USIntegral Molecular (United States) · USVanderbilt University · USWashington University in St. Louis · US

Funding

Antibody-based Protection against FlavivirsesR01AI073755 · NIAID · WASHINGTON UNIVERSITY · PI DIAMOND, MICHAEL S, FREMONT, DAVED H. · 2007 to 2022
$11.4M
Structure and Function of FlavivirusesR01AI076331 · NIAID · PURDUE UNIVERSITY · PI KUHN, RICHARD J. · 2008 to 2017
$6.8M
Human neutralizing antibodies for Zika virusR01AI127828 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CROWE, JAMES E, DIAMOND, MICHAEL S · 2017 to 2021
$3.9M
ISG CONTROL OF FLAVIVIRUS INFECTIONR01AI104972 · NIAID · WASHINGTON UNIVERSITY · PI CHANDA, SUMIT K, DIAMOND, MICHAEL S · 2013 to 2017
$3.0M
NIAID NIH HHS HHSN272201400024CNIAID NIH HHS HHSN272201400058CNIAID NIH HHS R01 AI073755NIAID NIH HHS R01 AI076331NIAID NIH HHS R01 AI104972NIAID NIH HHS R01 AI127828
6 · The paper itself

Abstract

Zika virus (ZIKV) is a major human pathogen and member of the

Indexed as

AnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralCryoelectron MicroscopyDisease Models, AnimalEpitopesHumansMaleMiceMice, Inbred C57BLVaccinationViral Envelope ProteinsZika VirusZika Virus InfectionAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralEpitopesViral Envelope Proteinscryo-EM structuremembrane-fusion inhibitionmonoclonal antibodyneutralization mechanismZika virus

Identifiers

PMID30642974
PMCPMC6358714
OpenAlexW2909755386

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.